Who owns ONCT - ONCTERNAL THERAPEUTICS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

ONCTERNAL THERAPEUTICS INC - COM (ONCT) Institutional Ownership

Q: What is CUSIP 68236P107?

CUSIP 68236P107 is the security identifier used in SEC filing datasets for ONCT - ONCTERNAL THERAPEUTICS INC - COM.

CUSIP: 68236P107

13F Institutional Holders and Ownership History from Q2 2019 to Q2 2024

Type / Class: Equity / COM
Symbol: ONCT on Nasdaq

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 68236P107?
CUSIP 68236P107 identifies ONCT - ONCTERNAL THERAPEUTICS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 68236P107:

Q2 2024 (0 holders) Q1 2024 (0 holders) Q4 2023 (36 holders) Q3 2023 (50 holders) Q2 2023 (52 holders) Q1 2023 (53 holders) Q4 2022 (58 holders) Q3 2022 (55 holders) Q2 2022 (67 holders) Q1 2022 (75 holders)

Institutional Holders of ONCTERNAL THERAPEUTICS INC - COM (ONCT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2024 Q2	0	$0	-$11				0
2024 Q1	0	$0	-$4,493,888				0
2023 Q4	8,387,387	$4,495,852	-$112,906			$0.54	36
2023 Q3	9,330,501	$2,805,800	-$68,051		$0	$0.30	50
2023 Q2	9,462,140	$3,263,960	-$512,023		$3,692	$0.34	52
2023 Q1	10,013,893	$7,847,971	+$474,820	$0	$7,144	$0.78	53
2022 Q4	9,366,691	$9,307,125	-$262,531	$1,300	$25,700	$1.00	58
2022 Q3	9,856,004	$8,784,878	-$1,691,314	$0	$56,251	$0.89	55
2022 Q2	11,386,807	$12,630,616	-$2,605,738	$19,000	$67,302	$1.11	67
2022 Q1	13,387,352	$18,626,136	-$589,229	$62,000	$17,000	$1.39	75
2021 Q4	13,411,190	$30,483,576	-$3,131,572	$71,000	$87,000	$2.27	81
2021 Q3	13,611,619	$56,781,839	-$929,861	$526,000	$1,192,000	$4.17	73
2021 Q2	13,719,592	$65,153,889	+$14,536,188	$1,556,000	$918,000	$4.75	82
2021 Q1	9,896,154	$82,459,538	+$20,558,773	$2,626,000	$1,005,000	$8.32	63
2020 Q4	8,416,056	$41,240,041	+$23,571,305	$228,000	$306,000	$4.90	51
2020 Q3	4,210,029	$7,156,000	+$2,559,637			$1.70	21
2020 Q2	2,703,001	$7,675,000	+$3,782,282			$2.84	18
2020 Q1	1,370,900	$4,017,012	+$322,769			$2.93	19
2019 Q4	1,259,576	$4,976,016	+$506,395			$3.95	20
2019 Q3	1,127,262	$5,635,485	+$4,105,983			$5.00	21
2019 Q2	289,418	$1,923,544	+$1,922,898			$6.65	21